Puma Biotechnology (NASDAQ: PBYI)
Puma Biotechnology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Puma Biotechnology Company Info
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
News & Analysis
Why Shares of Puma Biotechnology Rose This Week
The company's CEO bought $2.5 million worth of company stock.
Why Puma Biotechnology's Shares Jumped 20% on Monday
It may have benefited from positive news about another company's drug candidate.
Why Puma Biotechnology Shares Dropped 17.7% This Week
With no good news, the stock fell with the rest of the market.
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today
Investors piled into cancer stocks today. Here's why.
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature
Success in clinical trials doesn't guarantee success on the market.
Will Puma Biotechnology Break Out of Its Rut in 2020?
The company's only drug product encountered significant obstacles to increasing its market share in 2019, but investors can see a potential path to growth.
3 High-Risk, High-Reward Stocks That Have Massive Upside Potential
If you can handle the uncertainty, these small-cap stocks can make you very wealthy.
6 Healthcare Stocks That Could Make You Filthy Rich
These top growth stocks could dramatically improve your financial wellbeing.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.